To Evaluate Real-world Safety, Effectiveness and Appropriate Use of Micatrio® Combination Tablets Treatment in Patients With Hypertension

Boehringer Ingelheim

Status: Completed

Conditions: Hypertension

Treatments: Drug: T80/A5/H12.5 FDC

Study type: Observational

Funder types: Industry

Identifiers

NCT03021265

1348.6

Details and patient eligibility

About

Study to evaluate real-world safety, effectiveness and appropriate use of Micatrio® Combination Tablets treatment in patients with hypertension

Full description

Non-interventional study based on newly collected data. The study will consist of a baseline visit and follow-up visits at Week 4, 8, 12, 24, 36 and 52 for patients who have newly initiated Micatrio® Combination Tablets. The patients will be followed up until discontinuation of Micatrio® Combination Tablets treatment or the end of study.

All patients administrated Micatrio® Combination Tablets after the launch at the sites contracted with the sponsor will be registered.

Enrollment: 676 patients

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who are prescribed with Micatrio® Combination Tablets by the discretion of investigators based on the Japanese package insert
• Patients who have never been treated with Micatrio® Combination Tablets before enrolment

Exclusion criteria

Patients who are participating/planned to participate in a clinical trial

Trial design

676 participants in 1 patient group

T80/A5/H12.5 FDC

Description:

Patients with hypertension

Treatment:

Drug: T80/A5/H12.5 FDC